8 Result(s)

Article

Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol

In case of locally advanced and/or non-metastatic unresectable esophageal cancer, definitive chemoradiotherapy (CRT) delivering 50 Gy in 25 daily fractions in combination with platinum-based regimen remains th...

Anouchka Modesto, David Tougeron, Pierre Tremolières, Philippe Ronchin… in BMC Cancer (2023)

Article

Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

The use of oxaliplatin in digestive tract cancers could induce severe peripheral neuropathy (OIPN) decreasing the quality of life of patients and survivors. There is currently, no univocal treatment for these ...

Nicolas Kerckhove, David Tougeron, Côme Lepage, Denis Pezet… in BMC Cancer (2022)

Article

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) ...

Stefano Kim, Bruno Buecher, Thierry André, Marine Jary… in BMC Cancer (2020)

Article

Analysis of factors influencing molecular testing at diagnostic of colorectal cancer

The aim of the study was to evaluate the current rate of molecular testing prescription (KRAS codons 12/13, BRAF and microsatellite instability (MSI)) in newly diagnosed colorectal cancer (CRC) patients and to de...

Quentin Thiebault, Gautier Defossez, Lucie Karayan-Tapon, Pierre Ingrand… in BMC Cancer (2017)

Article

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Antoine Adenis, Christelle de la Fouchardiere, Bernard Paule, Pascal Burtin… in BMC Cancer (2016)

Article

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outc...

Antoine Adenis, Christelle de la Fouchardiere, Bernard Paule, Pascal Burtin… in BMC Cancer (2016)

Article

Genetic variations of the A13/A14 repeat located within the EGFR3′ untranslated region have no oncogenic effect in patients with colorectal cancer

The EGFR 3′ untranslated region (UTR) harbors a polyadenine repeat which is polymorphic (A13/A14) and undergoes somatic deletions in microsatellite instability (MSI) colorectal cancer (CRC). These mutations could...

Nasrin Sarafan-Vasseur, David Sefrioui, David Tougeron, Aude Lamy… in BMC Cancer (2013)

Article

Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes

Only limited data has been reported so far regarding oesophageal cancer (EC) in elderly patients. The aim of the study is to identify the baseline parameters that influenced therapeutic decision.

David Tougeron, Hadji Hamidou, Michel Scotté, Frédéric Di Fiore… in BMC Cancer (2010)